Wockhardt plunges 5% on USFDA‘s hygiene concerns

Wockhardt is locked in lower circuit of five percent at Rs 551 on the NSE after reports that United States Food and Drug Administration’s (FDA) inspection at the company’s Chikalthana plant found urine spilling over open drains. 

Also read: USFDA to Agila: Use of non-sterile gloves a grave violation

The US regulator’s assessment came up with 16 observations. It revealed that the plant had unhygienic toilets. Mold was growing in the storage areas of the factory. It also found soiled uniforms around the area.

The factory produces heart tablets called Toprol XL. Wockhardt currently holds 26 percent of Toprol XL market share in the US.